135 related articles for article (PubMed ID: 8072119)
1. Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity.
Cheng DL; Shu WP; Choi JC; Margolis EJ; Droller MJ; Liu BC
J Urol; 1994 Oct; 152(4):1275-80. PubMed ID: 8072119
[TBL] [Abstract][Full Text] [Related]
2. Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro.
Schneider B; Thanhäuser A; Jocham D; Loppnow H; Vollmer E; Galle J; Flad HD; Ulmer AJ; Böhle A
World J Urol; 1994; 12(6):337-44. PubMed ID: 7881473
[TBL] [Abstract][Full Text] [Related]
3. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy.
Shemtov MM; Cheng DL; Kong L; Shu WP; Sassaroli M; Droller MJ; Liu BC
J Urol; 1995 Jul; 154(1):269-74. PubMed ID: 7776443
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
[TBL] [Abstract][Full Text] [Related]
5. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guerin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction.
Garden RJ; Liu BC; Redwood SM; Weiss RE; Droller MJ
J Urol; 1992 Sep; 148(3):900-5. PubMed ID: 1512857
[TBL] [Abstract][Full Text] [Related]
7. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.
Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ
Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy.
Fleischmann JD; Park MC; Hassan MO
J Urol; 1993 Feb; 149(2):268-71. PubMed ID: 8426398
[TBL] [Abstract][Full Text] [Related]
9. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.
Campbell SC; Tanabe K; Alexander JP; Edinger M; Tubbs RR; Klein EA
J Urol; 1994 May; 151(5):1385-90. PubMed ID: 7908992
[TBL] [Abstract][Full Text] [Related]
10. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer.
Mizutani Y; Nio Y; Fukumoto M; Yoshida O
Cancer; 1992 Jan; 69(2):537-45. PubMed ID: 1728384
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
12. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
13. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity.
Zhao W; Schorey JS; Bong-Mastek M; Ritchey J; Brown EJ; Ratliff TL
Int J Cancer; 2000 Apr; 86(1):83-8. PubMed ID: 10728599
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.
Kavoussi LR; Brown EJ; Ritchey JK; Ratliff TL
J Clin Invest; 1990 Jan; 85(1):62-7. PubMed ID: 2404029
[TBL] [Abstract][Full Text] [Related]
15. In vitro generation of bacillus Calmette-Guérin-activated killer cells.
Brandau S; Böhle A; Thanhäuser A; Ernst M; Mattern T; Ulmer AJ; Flad HD
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S94-S100. PubMed ID: 11010832
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.
Patard JJ; Chopin DK; Boccon-Gibod L
World J Urol; 1993; 11(3):165-8. PubMed ID: 8401636
[TBL] [Abstract][Full Text] [Related]
17. Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
Danişman A; Bulut K; Kukul E; Ozen I; Sevük M
Urol Int; 2000; 64(4):198-201. PubMed ID: 10895085
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in transitional cancer cell lines.
Sandes E; Lodillinsky C; Cwirenbaum R; Argüelles C; Casabé A; Eiján AM
Int J Mol Med; 2007 Dec; 20(6):823-8. PubMed ID: 17982689
[TBL] [Abstract][Full Text] [Related]
19. Interaction between fibronectin-bearing surfaces and Bacillus Calmette-Guérin (BCG) or gelatin microparticles.
Lou Y; Olson WP; Tian XX; Klegerman ME; Groves MJ
J Pharm Pharmacol; 1995 Mar; 47(3):177-81. PubMed ID: 7602476
[TBL] [Abstract][Full Text] [Related]
20. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.
Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H
BJU Int; 2011 Nov; 108(9):1520-6. PubMed ID: 21314815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
